The Fast Company Impact Council consists of experts and entrepreneurs sharing insights on AI's role in the life sciences sector. While AI has significantly advanced drug discovery, personalized medicine, and disease diagnosis, the article emphasizes that human qualities such as empathy and creativity cannot be replicated by AI. These human aspects are critical for understanding patient needs and shaping the drug development process, which remains fundamentally tied to human experience. The author shares a case study illustrating the application of these principles in developing a treatment for Demodex blepharitis.
AI is not 'intelligent' when it comes to emotion, imagination, or empathy—qualities critical to creating and leading.
Despite the transformative potential of AI in drug discovery, it cannot replace the human experience in recognizing serendipity and patient needs.
Collection
[
|
...
]